Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of three components: - **Fm** (identity not specified in the available data; could refer to a research compound or abbreviation) - **SH** (identity not specified in the available data; could refer to a research compound, abbreviation, or chemical group such as "sulfhydryl") - **Cyclosporin A**, also known as ciclosporin or cyclosporine, is an immunosuppressant medication and calcineurin inhibitor. Cyclosporin A works by forming a complex with cyclophilin to inhibit calcineurin phosphatase activity, thereby suppressing T-cell activation and reducing immune responses. It is widely used for preventing organ transplant rejection and treating autoimmune diseases such as rheumatoid arthritis and psoriasis[1][3][5]. The combination may be experimental or investigational, as there are no approved products under this exact name in major regulatory databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fm + SH + cyclosporin A.